197 related articles for article (PubMed ID: 36041373)
1. Prognosis and oncogenomic profiling of patients with tropomyosin receptor kinase fusion cancer in the 100,000 genomes project.
Bridgewater J; Jiao X; Parimi M; Flach C; Stratford J; Kamburov A; Schmitz AA; Zong J; Reeves JA; Keating K; Bruno A; Fellous M; Pereira MB; Bazhenova L
Cancer Treat Res Commun; 2022; 33():100623. PubMed ID: 36041373
[TBL] [Abstract][Full Text] [Related]
2. TRK Fusion Cancer: Patient Characteristics and Survival Analysis in the Real-World Setting.
Bazhenova L; Lokker A; Snider J; Castellanos E; Fisher V; Fellous M; Nanda S; Zong J; Keating K; Jiao X
Target Oncol; 2021 May; 16(3):389-399. PubMed ID: 33893941
[TBL] [Abstract][Full Text] [Related]
3. China special issue on gastrointestinal tumors-NTRK fusion in a large real-world population and clinical utility of circulating tumor DNA genotyping to guide TRK inhibitor treatment.
Qi C; Zhou T; Bai Y; Chen H; Yuan J; Zhao F; Liu C; Ma M; Bei T; Chen S; Zhao X; Chen C; Shen L
Int J Cancer; 2023 Dec; 153(11):1916-1927. PubMed ID: 36946696
[TBL] [Abstract][Full Text] [Related]
4. ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer.
Pietrantonio F; Di Nicolantonio F; Schrock AB; Lee J; Tejpar S; Sartore-Bianchi A; Hechtman JF; Christiansen J; Novara L; Tebbutt N; Fucà G; Antoniotti C; Kim ST; Murphy D; Berenato R; Morano F; Sun J; Min B; Stephens PJ; Chen M; Lazzari L; Miller VA; Shoemaker R; Amatu A; Milione M; Ross JS; Siena S; Bardelli A; Ali SM; Falcone A; de Braud F; Cremolini C
J Natl Cancer Inst; 2017 Dec; 109(12):. PubMed ID: 29370427
[TBL] [Abstract][Full Text] [Related]
5. The Use of Pan-Tropomyosin Receptor Kinase Immunohistochemistry as a Screening Tool for the Detection of Neurotrophic Tropomyosin-Related Kinase Fusions: Real-World Data from a National Multicentric Retrospective Study.
Van Bockstal MR; Beniuga G; Craciun L; Creytens D; Dedeurwaerdere F; Delvenne P; Demetter P; De Wiest B; Dewinne K; Habran L; Pauwels P; Theate I; Vander Borght S; Van Der Steen K; Weynand B
Pathobiology; 2022; 89(6):393-406. PubMed ID: 35350025
[TBL] [Abstract][Full Text] [Related]
6. Timing of NTRK Gene Fusion Testing and Treatment Modifications Following TRK Fusion Status Among US Oncologists Treating TRK Fusion Cancer.
Klink AJ; Kavati A; Gassama AT; Kozlek T; Gajra A; Antoine R
Target Oncol; 2022 May; 17(3):321-328. PubMed ID: 35716252
[TBL] [Abstract][Full Text] [Related]
7. NTRK oncogenic fusions are exclusively associated with the serrated neoplasia pathway in the colorectum and begin to occur in sessile serrated lesions.
Kim JH; Hong JH; Choi YL; Lee JA; Seo MK; Lee MS; An SB; Sung MJ; Cho NY; Kim SS; Shin YK; Kim S; Kang GH
J Pathol; 2021 Dec; 255(4):399-411. PubMed ID: 34402529
[TBL] [Abstract][Full Text] [Related]
8. Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer.
Amatu A; Sartore-Bianchi A; Bencardino K; Pizzutilo EG; Tosi F; Siena S
Ann Oncol; 2019 Nov; 30(Suppl_8):viii5-viii15. PubMed ID: 31738427
[TBL] [Abstract][Full Text] [Related]
9. Frequent CD30 Expression in an Emerging Group of Mesenchymal Tumors With NTRK, BRAF, RAF1, or RET Fusions.
Kojima N; Mori T; Motoi T; Kobayashi E; Yoshida M; Yatabe Y; Ichikawa H; Kawai A; Yonemori K; Antonescu CR; Yoshida A
Mod Pathol; 2023 Apr; 36(4):100083. PubMed ID: 36788089
[TBL] [Abstract][Full Text] [Related]
10. NTRK fusion positive colorectal cancer is a unique subset of CRC with high TMB and microsatellite instability.
Wang H; Li ZW; Ou Q; Wu X; Nagasaka M; Shao Y; Ou SI; Yang Y
Cancer Med; 2022 Jul; 11(13):2541-2549. PubMed ID: 35506567
[TBL] [Abstract][Full Text] [Related]
11. Genomic Alterations of NTRK, POLE, ERBB2, and Microsatellite Instability Status in Chinese Patients with Colorectal Cancer.
Guo Y; Guo XL; Wang S; Chen X; Shi J; Wang J; Wang K; Klempner SJ; Wang W; Xiao M
Oncologist; 2020 Nov; 25(11):e1671-e1680. PubMed ID: 32627883
[TBL] [Abstract][Full Text] [Related]
12. ROS1 Fusions Rarely Overlap with Other Oncogenic Drivers in Non-Small Cell Lung Cancer.
Lin JJ; Ritterhouse LL; Ali SM; Bailey M; Schrock AB; Gainor JF; Ferris LA; Mino-Kenudson M; Miller VA; Iafrate AJ; Lennerz JK; Shaw AT
J Thorac Oncol; 2017 May; 12(5):872-877. PubMed ID: 28088512
[TBL] [Abstract][Full Text] [Related]
13. Real-world Experience With Neurotrophic Tyrosine Receptor Kinase Fusion-positive Tumors and Tropomyosin Receptor Kinase Inhibitors in Veterans.
Zhou KI; Vashistha V; Guo A; Ahmed S; Kelley MJ
JCO Precis Oncol; 2023 Mar; 7():e2200692. PubMed ID: 36926986
[TBL] [Abstract][Full Text] [Related]
14. Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population.
Westphalen CB; Krebs MG; Le Tourneau C; Sokol ES; Maund SL; Wilson TR; Jin DX; Newberg JY; Fabrizio D; Veronese L; Thomas M; de Braud F
NPJ Precis Oncol; 2021 Jul; 5(1):69. PubMed ID: 34285332
[TBL] [Abstract][Full Text] [Related]
15. Real-world survival outcomes in patients with locally advanced or metastatic NTRK fusion-positive solid tumors receiving standard-of-care therapies other than targeted TRK inhibitors.
Hibar DP; Demetri GD; Peters S; Davies J; Humblet O; Maund SL; Perez L
PLoS One; 2022; 17(8):e0270571. PubMed ID: 35939431
[TBL] [Abstract][Full Text] [Related]
16. Treatment Patterns of Real-World Patients with TRK Fusion Cancer Treated by US Community Oncologists.
Klink AJ; Kavati A; Gassama A; Kozlek T; Gajra A; Antoine R
Target Oncol; 2022 Sep; 17(5):549-561. PubMed ID: 36089643
[TBL] [Abstract][Full Text] [Related]
17. Phase separation underlies signaling activation of oncogenic NTRK fusions.
Zhu T; Xie J; He H; Li H; Tang X; Wang S; Li Z; Tian Y; Li L; Zhu J; Zhu G
Proc Natl Acad Sci U S A; 2023 Oct; 120(42):e2219589120. PubMed ID: 37812694
[No Abstract] [Full Text] [Related]
18. CANTRK: A Canadian Ring Study to Optimize Detection of NTRK Gene Fusions by Next-Generation RNA Sequencing.
Stockley TL; Lo B; Box A; Corredor AG; DeCoteau J; Desmeules P; Feilotter H; Grafodatskaya D; Greer W; Hawkins C; Huang WY; Izevbaye I; Lépine G; Martins Filho SN; Papadakis AI; Park PC; Riviere JB; Sheffield BS; Spatz A; Spriggs E; Tran-Thanh D; Yip S; Zhang T; Torlakovic E; Tsao MS
J Mol Diagn; 2023 Mar; 25(3):168-174. PubMed ID: 36586421
[TBL] [Abstract][Full Text] [Related]
19. NTRK gene fusions in melanoma: detection, prevalence and potential therapeutic implications.
Forschner A; Forchhammer S; Bonzheim I
J Dtsch Dermatol Ges; 2020 Dec; 18(12):1387-1392. PubMed ID: 32656925
[TBL] [Abstract][Full Text] [Related]
20. Detection of Tumor NTRK Gene Fusions to Identify Patients Who May Benefit from Tyrosine Kinase (TRK) Inhibitor Therapy.
Hsiao SJ; Zehir A; Sireci AN; Aisner DL
J Mol Diagn; 2019 Jul; 21(4):553-571. PubMed ID: 31075511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
